Advanced search
Publication Cover
Biologics: Targets and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
205
Views
3
CrossRef citations to date
0
Altmetric
Original Research

An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease

Tzu Hsiang Chien1 Janssen-Cilag Pty Ltd, Sydney, NSW, AustraliaCorrespondence[email protected]
View further author information
,
Andrea Puig1 Janssen-Cilag Pty Ltd, Sydney, NSW, AustraliaORCID Iconhttps://orcid.org/0000-0002-7730-6310View further author information
ORCID Icon,
Thang Khuong2 Prospection Pty Ltd, Sydney, NSW, AustraliaView further author information
,
Mahsa H Kouhkamari2 Prospection Pty Ltd, Sydney, NSW, AustraliaView further author information
,
Samuel Che2 Prospection Pty Ltd, Sydney, NSW, AustraliaView further author information
&
Tom Hsun-Wei Huang1 Janssen-Cilag Pty Ltd, Sydney, NSW, AustraliaORCID Iconhttps://orcid.org/0000-0001-7221-6423View further author information
ORCID Icon
Pages 237-245 | Published online: 16 Jun 2021

References

  • Australia, PricewaterhouseCoopers. Improving inflammatory bowel disease care across Australia. Commissioned by Crohns and Colitis Australia. 2013.
  • Wilson J, Hair C, Knight R, et al. High incidence of inflammatory bowel disease in Australia: a prospective population-based Australian incidence study. Inflamm Bowel Dis. 2010;16(9):1550–1556. doi:10.1002/ibd.21209
  • Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
  • Alex GA, Bell S, Connor S, Moore G, Ward M, Vn Langenberg D. Australian guidelines for general practitioners and physicians - inflammatory bowel disease 4th edition (updated 2018). Gastroenterol Soc Australia. 2018.
  • Janssen-Cliag. Stelara Ustekinumab Australian product information. 2020.
  • Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22. doi:10.1093/ecco-jcc/jjz180
  • Macaluso FS, Maida M, Ventimiglia M, Cottone M, Orlando A. Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies. Expert Opin Biol Ther. 2020;20(2):193–203. doi:10.1080/14712598.2020.1707800
  • Kakkadasam Ramaswamy P, Moattar H, Sawyer E, Edwards J, Shukla D. P697 Efficacy and safety of ustekinumab in Crohn’s disease: a real-world study from Australia. J Crohns Colitis. 2020;14(Supplement_1):S564–S565. doi:10.1093/ecco-jcc/jjz203.825
  • Mellish L, Karanges EA, Litchfield MJ, et al. The Australian pharmaceutical benefits scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8(1):634. doi:10.1186/s13104-015-1616-8
  • Paige E, Kemp-Casey A, Korda R, Banks E. Using Australian pharmaceutical benefits scheme data for pharmacoepidemiological research: challenges and approaches. Public Health Res Pract. 2015;25(4). doi:10.17061/phrp2541546
  • Ko Y, Paramsothy S, Leong R. P361 The effect of immunomodulators and other factors on the persistence of biological agents for Crohn’s disease and ulcerative colitis: data from the Australian population-based registry. J Crohns Colitis. 2020;14(Supplement_1):S342–S343. doi:10.1093/ecco-jcc/jjz203.490
  • Harris RJ, McDonnell M, Young D, et al. Early real-world effectiveness of ustekinumab for Crohn’s disease. Frontline Gastroenterol. 2020;11(2):111–116. doi:10.1136/flgastro-2019-101237
  • Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L. Treatment persistence for infliximab versus adalimumab in Crohn’s disease: a 14-year single-center experience. Inflamm Bowel Dis. 2017;23(6):976–985. doi:10.1097/MIB.0000000000001072
  • Dalal SR, Cohen RD. What to do when biologic agents are not working in inflammatory bowel disease patients. Gastroenterol Hepatol. 2015;11(10):657–665.
  • Fine S, Papamichael K, Cheifetz A. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2019;15(12):656–665.
  • Flanagan E, Gibson PR, Rosella O, et al. P683 Infliximab, adalimumab and vedolizumab levels are not altered by pregnancy progression in IBD patients and neonatal vedolizumab levels are lower than in mothers: results from the PICCOLO study. J Crohns Colitis. 2020;14:S556–S557. doi:10.1093/ecco-jcc/jjz203.811
  • Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507. doi:10.1111/jcpt.12830
  • Eberl A, Hallinen T, Af Bjorkesten CG, et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019;54(6):718–725. doi:10.1080/00365521.2019.1624817
  • Af Björkesten CG, Ilus T, Hallinen T, et al. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort. Eur J Gastroenterol Hepatol. 2020;32(12):1507–1513. doi:10.1097/MEG.0000000000001831
  • Obando C, Ding Z, Muser E, et al. Persistence, dose titration, and health care resource utilization among Crohn’s disease patients treated with Ustekinumab: a real-world analysis in the United States. Adv Ther. 2020;37(5):2127–2143. doi:10.1007/s12325-020-01276-3

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.